CD47-Engineered Exosomes for Targeted siRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting oncogenic Kras in pancreatic cancer are limited by cytotoxic effects and require careful dosage monitoring, and existing delivery approaches are inefficient for systemic administration.
Innovation Solution
Engineered liposomes and exosomes, isolated from cells overexpressing CD47, are used as delivery systems for therapeutic agents like siRNA and antibodies, specifically targeting KrasG12D mutations, minimizing cytotoxicity and improving systemic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNAi-based targeting of Kras is delivered using nanoparticles, then tumor burden is reduced, but cytotoxic effects are induced requiring careful dosage monitoring
Solution Approach 1:
The patent uses exosomes as intermediary carriers to deliver RNAi therapeutics. Exosomes are natural membrane vesicles that can be engineered to carry siRNA or shRNA targeting oncogenic Kras. These exosomal carriers protect the therapeutic cargo from degradation and enable targeted delivery to tumor cells while minimizing off-target cytotoxic effects, thus resolving the contradiction between effective tumor suppression and harmful side effects
Solution Approach 2:
The patent modifies the physical and chemical parameters of the delivery system by using exosomes with specific surface properties and cargo loading capacities. By controlling the RNAi cargo concentration within exosomes and engineering surface markers for targeted delivery, the system achieves effective intracellular delivery at lower doses, reducing cytotoxicity while maintaining tumor burden reduction
2Measurement precision
If electroporation or biopolymeric implants are used for Kras targeting, then specific targeting is achieved, but delivery efficiency for systemic administration is limited
Solution Approach 1:
The patent employs exosomes as natural intermediary vehicles that can be administered systemically. These exosomes can be engineered with specific surface markers or ligands that enable them to home to tumor cells expressing corresponding receptors. This approach combines the specificity of targeted delivery with the versatility of systemic administration, overcoming the limitations of electroporation and biopolymeric implants
Solution Approach 2:
The exosomal delivery system is designed to be universally applicable for systemic administration while maintaining targeting capability. The exosomes can carry various RNAi cargos targeting different oncogenes and can be directed to different tumor types by engineering appropriate surface markers, thus achieving both specificity and high delivery efficiency through a single versatile platform
Data Source
AI summary
The present invention provides lipid-based nanoparticles (e.g., liposomes or exosomes) having CD47 on their surface and comprising a therapeutic agent (e.g., a therapeutic protein, an antibody, an inhibitory RNA, and/or a small molecule drug). Furthermore, the present invention provides for use of such lipid-based nanoparticles in therapy.